Pneumococcal Conjugate Vaccines Archives

Merck makes waves in Q1 2022 with COVID-19 treatment, cancer portfolio

Breakthrough Therapy Designation, Business, COVID-19 Therapeutic, COVID-19 Therapeutics, COVID-19 Therapies, Earnings per share (EPS), Financials, Forecasts, Keytruda, Market Share, Merck, Pneumococcal Conjugate Vaccines, Pneumococcal Vaccines, Sales, Therapeutics

Merck announced the company’s Q1 2022 results, reporting year-over-year revenue growth of 50 percent from continuing operations, with worldwide sales increasing to $15.9 billion. As anticipated, Merck’s COVID-19 antiviral treatment Lagevrio (molnupiravir) played a role in the company’s robust sales.

U.S. FDA Approves Pfizer’s Prevnar 20

Adults, Advisory Committee on Immunization Practices (ACIP), Approvals, CDC, FDA, Pfizer, Pneumococcal Conjugate Vaccines, Pneumococcal Disease

The U.S. Food and Drug Administration approved Pfizer Inc.’s Prevnar 20 (Pneumococcal 20-valent Conjugate Vaccine) for the prevention of invasive disease and pneumonia caused by the 20 Streptococcus pneumoniae (pneumococcus) serotypes in the vaccine in adults ages 18 years and older.

Merck’s Pneumococcal Conjugate Vaccine Shows Promise in Children

Bacteria, Children, Clinical Trials, Merck, Pediatrics, Pneumococcal Conjugate Vaccines, R&D

Topline results from two of Merck’s Phase III pediatric trials show the company’s investigational 15-valent pneumococcal conjugate vaccine, V114, may be safe and effective in healthy children.